Loading
A phase 2/3 trial of Adebrelimab and SHR-A2102 in bladder & urothelial cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) is a phase 2/3 interventional study registered as NCT06879145 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 840 participants planned, started 2025-04-25 and due to reach its primary completion in 2031-12. Interventions recorded: SHR-A2102；Adebrelimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-A2102, Muscle-invasive and advanced bladder cancer, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares SHR-A2102, Muscle-invasive and advanced bladder cancer, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/